Craft

InVivo Therapeutics

Stock Price

$0.4

2024-04-15

Market Capitalization

$995.9 K

2024-04-15

InVivo Therapeutics Summary

Company Summary

Overview
InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company focused on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The Company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI, and Therapeutic Trails injection program for the treatment of chronic SCI.
Type
Public
Status
Active
Founded
2005
HQ
Cambridge, MA, US | view all locations
Website
http://www.invivotherapeutics.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Richard Christopher

    Richard Christopher, Chief Financial Officer

  • Heather Hamel

    Heather Hamel, Chief Legal Officer, General Counsel

  • William D'Agostino

    William D'Agostino, SVP Operations

  • Ann Merrifield

    Ann Merrifield, Chair of the Board

Operating MetricsView all

Patents (Foreign)

8

FY, 2016

Patents (US)

8

FY, 2016

Patents Pending

12

FY, 2016

LocationsView all

1 location detected

  • Cambridge, MA HQ

    United States

    One Kendall Square, Binney St

InVivo Therapeutics Financials

Summary Financials

Net income (Q3, 2023)
($2.7M)
Cash (Q3, 2023)
$8.6M
EBIT (Q3, 2023)
($2.8M)

Footer menu